Acerus Pharmaceuticals Corporation   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Mississaugua Canada (1983)
Status: Acquired by Biovail (1993) → now Bausch Health Companies (2010)

Organization Overview

First Clinical Trial
2009
NCT00975650
First Marketed Drug
2014
testosterone (delatestryl)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ACERUS | Acerus Biopharma Inc. | Acerus Pharmaceutical | Acerus Pharmaceuticals Corporation | Acerus Pharmaceuticals Corporation/ Aytu Biosciences Inc. | ACERUS PHARMS | Trimel Biopharma | Trimel Biopharma SRL | Trimel Corp | Trimel Pharmaceuticals Corporation

Active Ingredients

Marketed Drugs (2)

Key: Acerus Pharmaceuticals Corporation (1) Acquired (1)

desmopressin (ddavp) (2017)

testosterone (delatestryl) (2014)

Drugs in Phase 4 Trials (1)

testosterone (delatestryl) (11 trials)

Drugs in Phase 3 Trials (1)

Key: Acerus Pharmaceuticals Corporation (0) Acquired (1)

desmopressin (ddavp) (6 trials)

Drugs in Phase 2 Trials (2)

albuterol (proventil) (1 trial)

platelet-rich plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Cardiovascular Diseases (Phase 4)

Erectile Dysfunction (Phase 2)

Eunuchism (Phase 4)

Hypogonadism (Phase 4)

Sexual Dysfunctions, Psychological (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 4